Yingjian Liang1, Chengrui Zhu1, Yini Sun1, Zhiliang Li1, Liang Wang1, Yina Liu1, Xin Li1, Xiaochun Ma2. 1. Department of Critical Care Medicine, The First Hospital of China Medical University, North Nanjing Street 155, Shenyang, 110001, Liaoning Province, China. 2. Department of Critical Care Medicine, The First Hospital of China Medical University, North Nanjing Street 155, Shenyang, 110001, Liaoning Province, China. cmu1hicu2002@sina.com.
Abstract
BACKGROUND: Soluble CD40 ligand (sCD40L) exhibits proinflammatory and procoagulant effects. Recent data indicated that sCD40L plays a significant role in septic patients. The aim of the present study was to determine sCD40L changes in surgical patients without sepsis (SWS) and surgical sepsis patients (SS) during the first 3 days after intensive care unit (ICU) admission and to observe the association between sCD40L and mortality. METHODS: Time changes in sCD40L levels were assessed for 3 days after ICU admission in 49 patients with SS and compared with those in 19 SWS patients. Serum sCD40L concentration was detected by ELISA. Survival at 28 days served as the endpoint. RESULTS: SS had significantly higher sCD40L levels than SWS and control patients. We observed an association between sCD40L levels ≥1028.75 pg/mL at day 2 and 28-day mortality (odds ratio = 7.888; 95% confidence interval = 1.758 to 35.395; P = 0.007). We could not discover any significant differences in sex, presence of septic shock, site of infection, length of stay in the ICU, PaO2/FiO2 ratio, incidence of AKI, ARDS, or type of surgery between nonsurvivors and survivors. CONCLUSIONS: Septic patients show persistently higher circulating sCD40L levels in the first 3 days after ICU admission, and serum sCD40L levels are associated with the mortality of patients with sepsis. Thus, serum sCD40L may be used as a reliable biomarker and therapeutic target in sepsis.
BACKGROUND: Soluble CD40 ligand (sCD40L) exhibits proinflammatory and procoagulant effects. Recent data indicated that sCD40L plays a significant role in septic patients. The aim of the present study was to determine sCD40L changes in surgical patients without sepsis (SWS) and surgical sepsis patients (SS) during the first 3 days after intensive care unit (ICU) admission and to observe the association between sCD40L and mortality. METHODS: Time changes in sCD40L levels were assessed for 3 days after ICU admission in 49 patients with SS and compared with those in 19 SWS patients. Serum sCD40L concentration was detected by ELISA. Survival at 28 days served as the endpoint. RESULTS: SS had significantly higher sCD40L levels than SWS and control patients. We observed an association between sCD40L levels ≥1028.75 pg/mL at day 2 and 28-day mortality (odds ratio = 7.888; 95% confidence interval = 1.758 to 35.395; P = 0.007). We could not discover any significant differences in sex, presence of septic shock, site of infection, length of stay in the ICU, PaO2/FiO2 ratio, incidence of AKI, ARDS, or type of surgery between nonsurvivors and survivors. CONCLUSIONS: Septic patients show persistently higher circulating sCD40L levels in the first 3 days after ICU admission, and serum sCD40L levels are associated with the mortality of patients with sepsis. Thus, serum sCD40L may be used as a reliable biomarker and therapeutic target in sepsis.
Authors: David P Inwald; Saul N Faust; Paula Lister; Mark J Peters; Michael Levin; Robert Heyderman; Nigel J Klein Journal: Intensive Care Med Date: 2006-06-30 Impact factor: 17.440
Authors: K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips Journal: Proc Natl Acad Sci U S A Date: 2003-09-30 Impact factor: 11.205
Authors: R Phillip Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven A Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Crit Care Med Date: 2013-02 Impact factor: 7.598
Authors: Leonardo Lorente; María M Martín; Nerea Varo; Juan María Borreguero-León; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Alejandro Jiménez; Eduardo Pastor; Felipe Belmonte; Josune Orbe; José A Rodríguez; Eduardo Gómez-Melini; José M Ferrer-Agüero; José Ferreres; María C Llimiñana; José A Páramo Journal: Crit Care Date: 2011-03-15 Impact factor: 9.097
Authors: Sandro Félix Perazzio; Paulo Vitor Soeiro-Pereira; Viviane Cardoso Dos Santos; Marlon Vilela de Brito; Bruno Salu; Maria Luiza Vilela Oliva; Anne Margherite Stevens; Alexandre Wagner Silva de Souza; Hans D Ochs; Troy R Torgerson; Antonio Condino-Neto; Luis Eduardo Coelho Andrade Journal: Arthritis Res Ther Date: 2017-10-19 Impact factor: 5.156